Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk
Introduction
Several polymorphic genes, encoding for enzymes involved in the biotransformation of carcinogens, have been studied as possible cancer risk modifiers. Most tobacco pro-carcinogens, as benzo[a]pyrene (BP), are activated by phase I enzymes to ultimate reactive intermediates which bind to DNA and induce mutations in critical hotspots [1]. Therefore, genetic variability in phase I activation and phase II detoxication has been postulated as a possible determinant of cancer susceptibility [2]. Cancers of the upper aerodigestive tract, as laryngeal carcinoma, strongly associated with tobacco smoke, alcohol and other possible exogenous risk factors, are currently investigated in relation to enzymes involved in bioactivation/deactivation reactions as microsomal epoxide hydrolase (EH, E.C. 3.3.2.3) and glutathione-S transferases (GSTs, EC 2.5.1.18).
Both EH and GSTs are enzymes involved in the metabolism of reactive intermediates, notably polycyclic aromatic hydrocarbons (PAHs) of tobacco smoke. EH is generally viewed as an inactivation enzyme since it catalyses the conversion of highly reactive epoxides to dihydrodiols [3]. However, some dihydrodiols can be subsequently metabolized to highly mutagenic polycyclic hydrocarbon diol epoxides. Therefore, EH can play a dual role in the activation/detoxication of procarcinogens. The EH enzyme is encoded by a single gene (EPHX1) in 1p11-qter [4], [5] and two polymorphic sites have been reported within the coding region. An exon 3 polymorphism results in a Tyr→His substitution in residue 113 and an exon 4 polymorphic site results in a 139 His→Arg substitution [6], [7]. According to in vitro studies, these exon 3 and 4 substitutions may, respectively, decrease and increase EH activity in tissues [8].
Several GST genes are also polymorphic in humans [9], [10]. The GSTM1 gene (1p13), encoding for a mu-GST isoenzyme, is known to exist in two allelic forms (GSTM1*A/GSTM1*B) and is deleted (GSTM1*0/0) in about 50% of caucasian individuals. Another GSTM gene of the same cluster (GSTM3) presents an intronic polymorphic site (3 bp deletion in intron 6), while GSTT1 (22q 11.2), encoding for a theta-GST isoenzyme, is also frequently deleted (GSTT1*0) among caucasians. GSTP1 (11q3) encodes for a pi-GST isoenzyme heavily expressed in the digestive and respiratory epithelium, is found in humans in two allelic forms (GSTP1*A/GSTP1*B) with an A→G substitution at exon 5 causing an 105Ile→105Val replacement within the active site of the protein [11], [12].
Most of the GST polymorphisms have been investigated in relation to various types of tobacco-related cancers as lung and upper aerodigestive tract tumours, without definitive conclusions [13]. Regarding larynx cancer, possible associations with either GSTM1 null, GSTT1 null, GSTM3 or GSTP1 have been reported [14], [15], [16], [17], [18], [19], [20]. The role of the EH polymorphisms on cancer risk is also controversial, with discrepant results being found in the literature [21], [22], [23], [24], [25], [26]. In a recent study, however, we found an interaction between EH and GSTP1 that increased lung cancer risk among Spanish caucasians [27]. This suggested the possibility of a combined role of two or more genes on BP activation/deactivation ratio. In the present study, we have addressed this possibility by studying the risk associated with the polymorphisms of EH and GST alone and in combination, on squamous cell carcinoma of the larynx.
Section snippets
Material and methods
The study involved a group of 204 patients with larynx cancer and a control group of 203 healthy volunteers. All cases and controls were Spanish caucasians, as judged by their names and places of birth, with residence in the area of Barcelona (Catalonia).
The cases were patients diagnosed of squamous cell carcinoma (SCC) of the larynx (126 glottic, 78 supraglottic) who underwent partial or total laryngectomy at the ‘Hospital Clı́nic’ or ‘Hospital Prı́nceps d'Espanya’, University of Barcelona,
Results
The distribution of the GSTM1null, GSTM1A/B, GSTT1, GSTP1 and GSTM3 among the controls and the patients can be found in Table 1. We found among the healthy controls, GST frequencies that were, in most cases, in accordance with other studies performed among European caucasians. The two GST gene deletions (GSTM1*0/0 and GSTT1*0/0) showed high frequency among the control group. GSTM1 was found to be deleted in nearly 50% of individuals which is in close agreement with the GSTM1*0/0 frequency among
Discussion
Our results among Spanish caucasians do not support the hypothesis that any of the single polymorphisms studied is associated with laryngeal cancer. In some cases, this conclusion is in contradiction with other phenotyping or genotyping studies that reported increased risks associated with some of the GST variants [17]. Most notably, we did not find any over-representation of patients with the GSTM1 null genotype as had been reported by some early studies among caucasians [18]. A similar trend,
Acknowledgements
This study was supported by Spanish ‘Fondo de Investigación Sanitaria’ (grant no. 00/0504)
References (43)
- et al.
The human microsomal epoxide hydrolase gene (EPHX1): complete nucleotide sequence and structural characterization
Genomics
(1994) - et al.
Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression
Arch. Biochem. Biophys.
(1997) - et al.
Epoxide hydrolase polymorphism and role in toxicology
Toxicol. Lett.
(2000) - et al.
Molecular cloning, characterization and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferases Pi gene variants
J. Biol. Chem.
(1997) - et al.
Glutathione S-transferase polymorphisms: influence on susceptibility to cancer
Chem. Biol. Interact.
(1998) - et al.
Genetic deletions of glutathione-S-transferase as a risk factor in squamous cell carcinoma of the larynx: a preliminary report
Am. J. Otolaryngol.
(2001) - et al.
Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles county
Lung Cancer
(2000) - et al.
Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1
Cancer Lett.
(2001) - et al.
Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7β,8α-dihydroxy-9α,10α-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene
Biochem. Biophys. Res. Commun.
(1997) - et al.
Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
Science
(1996)
Genetic variability in susceptibility and response to toxicants
Toxicol. Lett.
Mammalian epoxide hydrolases: inducible enzymes catalyzing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds
Xenobiotica
Assignment of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization
Cytogenet. Cell Genet.
Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants
Hum. Mol. Genet.
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
Crit. Rev. Biochem. Mol. Biol.
Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13–14
Ann. Hum. Genet.
Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties
Eur. J. Biochem.
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking
Cancer Epidemiol. Biomarkers Prev.
Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk
Cancer Epidemiol. Biomarkers Prev.
Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers
Clin. Chem. Lab. Med.
Glutathione and glutathione S-transferases in human squamous cell carcinomas of the larynx and GSTM1 dependent risk
Anticancer Res.
Cited by (61)
Discovery of soluble epoxide hydrolase inhibitors from natural products
2014, Food and Chemical ToxicologyCitation Excerpt :In the present study, we developed a method for testing mEH inhibition and evaluated the mEH inhibitory potential of compounds with sEH inhibitory activity, to determine the selectivity of sEH inhibitors. mEH is the first-line defense against xenobiotic-derived epoxide (Oesch, 1973), and mEH polymorphism is associated with several diseases and cancers (Smith and Harrison, 1997; To-Figueras et al., 2002; Kiyohara et al., 2002; Baxter et al., 2002). Thus, the inhibition of mEH may augment toxicity induced by epoxides.
Development of fluorescent substrates for microsomal epoxide hydrolase and application to inhibition studies
2011, Analytical BiochemistryGenetic polymorphisms in metabolizing enzymes and susceptibility of chromosomal damage induced by vinyl chloride monomer in a Chinese worker population
2010, Journal of Occupational and Environmental MedicineCypa: A potential target of tumor radiotherapy and/or chemotherapy
2021, Current Medicinal Chemistry